{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061119","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.633721+00:00","generated_at":"2026-06-08T09:30:01.153995+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec","bullets":["Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.","XEN1101 Phase 2 X-NOVA MDD trial topline results expected late November to mid-December 2023.","Phase 3 epilepsy trials X-TOLE2, X-TOLE3, X-ACKT ongoing; X-TOLE2 enrollment to complete H2 2024.","Neurocrine to report NBI-921352 adult focal study data in November 2023.","R&D expenses increased to $42.9M from $29.4M, driven by XEN1101 clinical advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061119","json":"https://secwatch.observer/filing/0000950170-23-061119.json","markdown":"https://secwatch.observer/filing/0000950170-23-061119.md","text":"https://secwatch.observer/filing/0000950170-23-061119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/0000950170-23-061119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/xene-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:30:01.153995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cdf5567871b55da4e561a66dabaa6a03842f6c8d","claim":"Xenon Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue No revenue was recognized.","evidence_excerpt":"Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/0000950170-23-061119-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"No revenue was recognized"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}